Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Chuikyo Subcommittee OKs 5-Scale Rating for Cost Effective Assessments
March 16, 2017
- Spontaneous Reporting Required Even When Causal Relationship Is Unclear: MHLW
March 16, 2017
- Chuikyo Approves Optimal Use Promotion Guidelines for Repatha, Praluent
March 16, 2017
- Ex-Minister Tamura, 17 Healthcare Leaders to Launch Study Group
March 15, 2017
- MHLW to Up Ante on Drug Distribution, Launch Panel on March 29: Minister
March 15, 2017
- PMDA’s FY2017 Project Plan Sets Higher Goal for Standard Product Review
March 15, 2017
- PMDA Approves Draft Budget for FY2017
March 15, 2017
- PMDA’s Steering Committee Discusses Fines, Regulatory Revision in Wake of Kaketsuken Scandal
March 15, 2017
- Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- Orphan Status Withdrawn for 4 Flu Vaccines: MHLW Notification
March 13, 2017
- MHLW to Stockpile Enough Avigan for 30,000 Persons
March 13, 2017
- Drug Prices Should Be Raised for Products with Good Outcomes: Shiozaki
March 10, 2017
- Change Necessary for Ethical Drug Distribution Rules, Shiozaki Says after Fake Harvoni Fuss
March 10, 2017
- Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
- NIBIOHN Looks to Spur Next-Gen Drug Development with Unique Antibody Techs, Joins Hands with 10 Companies
March 9, 2017
- MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
- MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
March 8, 2017
- Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…